AR040623A1 - Vacuna contra el virus de la aftosa. - Google Patents
Vacuna contra el virus de la aftosa.Info
- Publication number
- AR040623A1 AR040623A1 AR20020101563A ARP020101563A AR040623A1 AR 040623 A1 AR040623 A1 AR 040623A1 AR 20020101563 A AR20020101563 A AR 20020101563A AR P020101563 A ARP020101563 A AR P020101563A AR 040623 A1 AR040623 A1 AR 040623A1
- Authority
- AR
- Argentina
- Prior art keywords
- construct
- ifn
- vaccine
- vector
- fmdv
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 3
- 102000006992 Interferon-alpha Human genes 0.000 abstract 2
- 108010047761 Interferon-alpha Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 abstract 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 108700005077 Viral Genes Proteins 0.000 abstract 1
- 239000007975 buffered saline Substances 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/135—Foot- and mouth-disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28634501P | 2001-04-26 | 2001-04-26 | |
| US10/128,463 US8058248B2 (en) | 2001-04-26 | 2002-04-24 | Foot and mouth disease virus vaccine comprising interferons |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040623A1 true AR040623A1 (es) | 2005-04-13 |
Family
ID=26826603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20020101563A AR040623A1 (es) | 2001-04-26 | 2002-04-29 | Vacuna contra el virus de la aftosa. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8058248B2 (OSRAM) |
| EP (1) | EP1389043B1 (OSRAM) |
| JP (1) | JP2004530677A (OSRAM) |
| CN (1) | CN100422322C (OSRAM) |
| AR (1) | AR040623A1 (OSRAM) |
| AT (1) | ATE437656T1 (OSRAM) |
| AU (1) | AU2002303503B2 (OSRAM) |
| BR (1) | BR0209251A (OSRAM) |
| CA (1) | CA2445266A1 (OSRAM) |
| DE (1) | DE60233127D1 (OSRAM) |
| MX (1) | MXPA03009763A (OSRAM) |
| NZ (1) | NZ529305A (OSRAM) |
| WO (1) | WO2002087336A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1951297A2 (en) * | 2005-11-10 | 2008-08-06 | GenVec, Inc. | Adenoviral vector-based foot-and-mouth disease vaccine |
| CN100572541C (zh) * | 2007-05-28 | 2009-12-23 | 中国农业科学院兰州兽医研究所 | 口蹄疫病毒双效疫苗载体、其制备方法及应用 |
| WO2011091027A2 (en) * | 2010-01-19 | 2011-07-28 | The United States Of America, As Represented By The Secretary Of Agriculture | Recombinant live attenuated foot-and-mouth disease (fmd) vaccine containing mutations in the l protein coding region |
| CN102226198B (zh) * | 2011-04-25 | 2016-04-06 | 中国农业科学院兰州兽医研究所 | 对口蹄疫病毒有抑制作用的干扰靶序列 |
| GB201111183D0 (en) * | 2011-06-30 | 2011-08-17 | Animal Health Inst | Peptide |
| CN102988970B (zh) * | 2011-09-19 | 2014-06-18 | 内蒙古必威安泰生物科技有限公司 | 口蹄疫纯化疫苗及其制备方法和应用 |
| CN102363043B (zh) * | 2011-10-09 | 2013-05-01 | 中国农业科学院兰州兽医研究所 | 一种猪用c型口蹄疫基因工程疫苗佐剂及其制备方法 |
| KR101329348B1 (ko) * | 2012-05-31 | 2013-11-15 | 대한민국 | 돼지 인터페론 알파-돼지 인터페론 감마를 동시 발현하는 재조합 아데노바이러스 |
| CN103592441B (zh) * | 2013-10-29 | 2015-06-17 | 王明丽 | 一种重组猪干扰素ɑ双抗体夹心法免疫胶体金检测试纸条的制备方法 |
| CN106546747B (zh) * | 2016-10-31 | 2019-03-01 | 江苏众红生物工程创药研究院有限公司 | 一种干扰素生物学活性的检测方法 |
| CN108103034B (zh) * | 2017-12-15 | 2022-06-24 | 云南农业大学动物医学院 | 同时表达A型、O型和Asia-1型口蹄疫病毒VP1基因重组腺病毒、构建方法及应用 |
| CN110343164A (zh) * | 2019-08-22 | 2019-10-18 | 安阳工学院 | 一种高活性7位点突变的猪干扰素α突变体及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5831023A (en) * | 1982-11-01 | 1998-11-03 | Genentech, Inc. | Recombinant animal interferon polypeptides |
| US4795436A (en) * | 1983-11-14 | 1989-01-03 | Bio-Mimetics, Inc. | Bioadhesive composition and method of treatment therewith |
| US4732971A (en) * | 1985-06-03 | 1988-03-22 | Eli Lilly And Company | Synthetic vaccines for foot and mouth disease |
| US5672510A (en) * | 1990-01-19 | 1997-09-30 | Genetic Therapy, Inc. | Retroviral vectors |
| US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| CN1054544C (zh) * | 1993-10-21 | 2000-07-19 | 复旦大学 | 家畜口蹄疫病毒多肽疫苗及其制备方法 |
| US5739118A (en) * | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US6045802A (en) * | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| US6221361B1 (en) * | 1995-01-19 | 2001-04-24 | Syntro Corporation | Recombinant swinepox virus |
| US5612040A (en) * | 1995-04-07 | 1997-03-18 | The United States Of America As Represented By The Secretary Of Agriculture | Non-infectious foot-and-mouth disease viruses |
| US5824316A (en) * | 1996-05-24 | 1998-10-20 | The United States Of America As Represented By The Secretary Of Agriculture | Leader-proteinase deleted foot-and-mouth disease viruses and their use as vaccines |
| DE19638044A1 (de) * | 1996-09-18 | 1998-03-19 | Bayer Ag | Immunogene Peptide von Maul- und Klauenseuchen-Viren |
| ES2136583T1 (es) * | 1996-10-18 | 1999-12-01 | Canji Inc | Procedimientos y composiciones para el suministro y expresion de acidos nucleicos de interferon alfa. |
| CN1181422A (zh) * | 1996-10-31 | 1998-05-13 | 上海市肿瘤研究所 | 与生长因子受体结合的多肽所构建的基因转移载体 |
| EE04873B1 (et) * | 1997-08-29 | 2007-08-15 | Biogen, Incorporated | Interferoon-beeta valku kodeerivat geeni sisaldava viirusvektori ja replikatsioonipuudega viirusvektori kasutamine |
| WO2000027198A1 (en) * | 1998-11-09 | 2000-05-18 | Abraham Nader G | Retroviral vectors encoding interferon alpha and uses thereof |
| US6544780B1 (en) * | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
-
2002
- 2002-04-24 US US10/128,463 patent/US8058248B2/en not_active Expired - Fee Related
- 2002-04-26 AU AU2002303503A patent/AU2002303503B2/en not_active Ceased
- 2002-04-26 WO PCT/US2002/013247 patent/WO2002087336A1/en not_active Ceased
- 2002-04-26 NZ NZ529305A patent/NZ529305A/en not_active IP Right Cessation
- 2002-04-26 EP EP02731528A patent/EP1389043B1/en not_active Expired - Lifetime
- 2002-04-26 MX MXPA03009763A patent/MXPA03009763A/es not_active Application Discontinuation
- 2002-04-26 AT AT02731528T patent/ATE437656T1/de not_active IP Right Cessation
- 2002-04-26 BR BR0209251-4A patent/BR0209251A/pt not_active IP Right Cessation
- 2002-04-26 DE DE60233127T patent/DE60233127D1/de not_active Expired - Fee Related
- 2002-04-26 CA CA002445266A patent/CA2445266A1/en not_active Abandoned
- 2002-04-26 JP JP2002584701A patent/JP2004530677A/ja active Pending
- 2002-04-26 CN CNB028129504A patent/CN100422322C/zh not_active Expired - Fee Related
- 2002-04-29 AR AR20020101563A patent/AR040623A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60233127D1 (OSRAM) | 2009-09-10 |
| EP1389043B1 (en) | 2009-07-29 |
| ATE437656T1 (de) | 2009-08-15 |
| CN100422322C (zh) | 2008-10-01 |
| CA2445266A1 (en) | 2002-11-07 |
| WO2002087336A1 (en) | 2002-11-07 |
| CN1533242A (zh) | 2004-09-29 |
| JP2004530677A (ja) | 2004-10-07 |
| EP1389043A1 (en) | 2004-02-18 |
| BR0209251A (pt) | 2005-02-09 |
| MXPA03009763A (es) | 2004-07-30 |
| NZ529305A (en) | 2005-08-26 |
| US20030171314A1 (en) | 2003-09-11 |
| AU2002303503B2 (en) | 2007-09-20 |
| EP1389043A4 (en) | 2004-09-08 |
| US8058248B2 (en) | 2011-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040623A1 (es) | Vacuna contra el virus de la aftosa. | |
| DE60121136D1 (de) | Proteasom-influenzavirus-impfstoffzusammensetzung | |
| Gierynska et al. | Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes | |
| DE69529748D1 (de) | Polynukleotide vakzine gegen den papilloma virus | |
| ES2191929T3 (es) | Respuestas inmunologicas contra los antigenos pvh estimuladas por composiciones que comprenden un antigeno pvh y una proteina de estres o un vector de expresion capaz de expresar dichas proteinas. | |
| MXPA05012788A (es) | Analogos de nucleosidos fluorados modificados. | |
| PE20030285A1 (es) | Vacunacion en dosis unica con mycoplasma hyopneumoniae | |
| NO20015073D0 (no) | Vaksiner | |
| AR011216A1 (es) | Una vacuna a base de antigenos superficiales contra la gripe, un metodo para prepararla y un metodo para la preparacion de proteinas antigenicas superficiales a partir de virus de gripe propagados sobre un cultivo celular animal | |
| UY27466A1 (es) | Métodos y composiciones para el tratamiento de hepatitis c virus con 4'-modificaciones nucleosides | |
| CZ298898B6 (cs) | Vakcína obsahující gen bovinního respiracního syncytiálního viru pro vakcinaci skotu proti respiracním nemocem | |
| HRP20040195B1 (hr) | Cjepivo protiv bolesti zapadnoga nila | |
| ATE417097T1 (de) | Rekombinantes respiratorische synzytialvirus expressionssystem und impfstoffe | |
| Lingnau et al. | Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines | |
| EA199800746A1 (ru) | Способ генерации противовирусного иммунного ответа у человека или животного | |
| BR0316346A (pt) | Vacina para vìrus do nilo ocidental | |
| AR041964A1 (es) | Vacuna de vhc que comprende un polinucleotido | |
| ATE473236T1 (de) | Antigene von piscirickettsia salmonis und deren verwendung | |
| WO2017004567A1 (en) | Compositions and methods for combination therapy with dengue virus and dendritic cells | |
| CU20120057A7 (es) | Composición vacunal contra el virus del dengue, kit y plásmido | |
| IL153775A0 (en) | Immunizing fish against viral infection | |
| Kim et al. | Generation of VHSV replicon particles carrying transmembrane and C-terminal cytoplasmic region-deleted G gene (rVHSV-GΔTM) and comparison of vaccine efficacy with G gene-deleted VHSV (rVHSV-ΔG) | |
| CO5300406A1 (es) | Vacuna | |
| Woolard et al. | Viral vaccines and CTL response | |
| TW200509964A (en) | VP1 of foot-and-mouth disease virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |